Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Spyridon P. Nikas"'
Autor:
Dalal Alkhelb, Christos Iliopoulos-Tsoutsouva, Spyridon P. Nikas, Michael S. Malamas, Alexandros Makriyannis, Rajeev I. I. Desai
Publikováno v:
ASPET 2023 Annual Meeting Abstract - Central Nervous System Pharmacology - Behavioral.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8aeadba3a40cd1f288bd39e0ddf57bb7
https://doi.org/10.1124/jpet.122.264140
https://doi.org/10.1124/jpet.122.264140
Autor:
Dalal A. Alkhelb, Andre Kirunda, Ioannis Papanastasiou, Shan Jiang, Christos Iliopoulos‐Tsoutsouvas, Alexander Zvonok, Spyridon P. Nikas, Kiran Vemuri, Alexandros Makriyannis, Rajeev I. Desai
Publikováno v:
The FASEB Journal. 36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6be66e0481454c8bcc61027bdb5248ae
https://doi.org/10.1096/fasebj.2022.36.s1.r4829
https://doi.org/10.1096/fasebj.2022.36.s1.r4829
Autor:
Ganeshsingh A. Thakur, Alexandros Makriyannis, Keith A. Sharkey, Alex Straiker, Catherine M. Keenan, Mohammad Bashashati, Ken Mackie, Marsha R. Eno, JodiAnne T. Wood, Martin Storr, Jim Wager-Miller, Huang-Ming Hu, Spyridon P. Nikas
Publikováno v:
British Journal of Pharmacology. 172:2406-2418
Background and Purpose Cannabinoid (CB) ligands have been demonstrated to have utility as novel therapeutic agents for the treatment of pain, metabolic conditions and gastrointestinal (GI) disorders. However, many of these ligands are centrally activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0230a556852ffb7f874ec57ec3faeca8
https://doi.org/10.1111/bph.13069
https://doi.org/10.1111/bph.13069
Autor:
Brian D. Kangas, Marcus S. Delatte, Ganesh A. Thakur, Kumara V. Subramanian, V. Kiran Vemuri, Alexandros Makriyannis, Jack Bergman, Spyridon P. Nikas, Vidyanand G. Shukla
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 344:561-567
Cannabinoid receptor 1 (CB(1)) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications. Recent laboratory studies suggest that the effects of CB(
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f82d50dfb53917abdc0c5aa13bf37945
https://doi.org/10.1124/jpet.112.201962
https://doi.org/10.1124/jpet.112.201962
Cannabinoid CB1 and serotonin 5‐HT1A agonists mediate lower lip retraction by independent mechanisms
Publikováno v:
The FASEB Journal. 26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc65df6699587118d3c61ac0de768441
https://doi.org/10.1096/fasebj.26.1_supplement.661.8
https://doi.org/10.1096/fasebj.26.1_supplement.661.8